SCHEMBL26154073

SCHEMBL26154073

COc1ccc(C(O)C2CCC2)cn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRNA7 P36544 1/20 0.40
▸ DHODH Q02127 1/20 0.39
▸ NNMT P40261 1/20 0.38
▸ HRH3 Q9Y5N1 1/20 0.37
▸ PTGS2 P35354 1/20 0.37
▸ KMT2A Q03164 2/20 0.36
▸ SLC6A2 P23975 2/20 0.36
▸ SLC6A4 P31645 2/20 0.36
▸ SLC6A3 Q01959 2/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ ITGB1 P05556 1/20 0.35
▸ ITGA4 P13612 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ MKNK1 Q9BUB5 1/20 0.35
▸ MKNK2 Q9HBH9 1/20 0.35
▸ CYP2A6 P11509 1/20 0.35
▸ CHRNB2 P17787 2/20 0.35
▸ CHRNA4 P43681 2/20 0.35
▸ CHRNB4 P30926 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16763014 0.94 CHRNA7 (0.41) CHRNA7NNMTKMT2AALDH1A1POLB
SCHEMBL18228247 0.76 NNMT (0.47) CHRNA7NNMTKMT2AALDH1A1POLB
SCHEMBL29078027 0.76 DHODH (0.44) DHODHHRH3KMT2ASLC6A3MEN1
SCHEMBL30108570 0.74 NNMT (0.46) CHRNA7NNMTKMT2AALDH1A1POLB
SCHEMBL1581887 0.74 NNMT (0.46) CHRNA7NNMTKMT2AALDH1A1POLB
SCHEMBL996927 0.73 CYP3A4 (0.47) CHRNA7NNMTKMT2AALDH1A1POLB
SCHEMBL16762977 0.73 LMNA (0.42) CHRNA7NNMTKMT2AALDH1A1POLB
SCHEMBL4549076 0.73 PIK3CA (0.39) CHRNA7NNMTHRH3MKNK1MKNK2
SCHEMBL26154072 0.72 P2RX7 (0.41) HRH3PTGS2
Hydrochloric Acid SCHEMBL2700952 0.72 PIK3CA (0.38) CHRNA7NNMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230157996-A1 SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF Shenzhen Bay Laboratory (CN) 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230157996-A1 SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF SSB, EBNA1BP2, PML CHRNA7 3179/4885DHODH 4681/4885NNMT 1211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback